Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Frequently Asked Questions / Types of Cancer / Lymphomas / Hodgkin's Disease
John Han-Chih Chang, MD
Last Modified: November 1, 2001
Dear OncoLink "Ask the Experts,"
Your article on the long-term effects of radiation failed to mention the connection between radiation therapy and breast cancer. There have been many articles including the Journal of the National Cancer Institute, Journal of the American Medical Association, New England Journal of Medicine and the Southern Medical Journal. Many young adolescents and teen girls, who received radiation therapy for Hodgkin's disease in the1980ss are unaware of the risks and not seeking the proper follow up.
Thanks,
VG, a VC and breast cancer survivor
John Han-Chih Chang, MD, OncoLink Editorial Assistant, responds:
Dear VG,
Thank you for your interest and voicing your concern.
The Frequently Asked Question document you had mentioned addressed the issues surrounding the etiology of diabetes and hypothyroidism. The possibility of radiation therapy being at the root of those two problems was discussed to directly respond to the inquiry.
The question of second malignancies in patients treated for Hodgkin's disease in their adolescence is a complicated one. Is there a higher propensity for patients who have had Hodgkin's disease to have another cancer, is it because of the treatment they received, or is it for both reasons that these patients have a higher risk?
Regardless, a preponderance of data demonstrate an increased rate of second malignancies in patients treated for Hodgkin's disease with radiation with or without chemotherapy. The types of cancers include but are not limited to breast cancer, lung cancer, non-Hodgkins lymphoma, sarcomas and leukemias (mostly chemotherapy associated). The latent period is over 10 or leukemias (6 . The estimated actuarial risk of any second neoplasms at 15 years after diagnosis is approximately 5 cancer risk of 2% estimated 20 years from diagnosis for all female Hodgkin's disease patients (treated in child- or adulthood). Data from Stanford University on nearly 700 patients treated for childhood Hodgkin's disease suggest a 9% risk of developing breast cancer at 20 years from diagnosis. The New England Journal of Medicine published a review on over 1300 patients with childhood Hodgkin's treated before the age of 16 years. They described the breast cancer risk to be as high as 35% by the age of 40 years, which is higher than other reports.
The risk of second malignancies is at least 2 if they were treated during childhood or adolescence. Recommendations are for routine follow-up on an every 6 month basis (at the very least) along with monthly breast self-examinations. Screening exams should begin earlier than the recommended time period for average women.
Here are some references for a more in depth review of the subject:
Dr. Metz talks about how caring for cancer patients has affected his life. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

